



SAFETY DATA SHEET

Revision date 06-Dec-2021

Version 1.02

Page 1 / 12

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

| | |
|-------------------------|---------------------------------------|
| Product Name | Epinephrine Injection (Hospira, Inc.) |
| Product Code(s) | PZ03223 |
| Trade Name: | Not applicable |
| Chemical Family: | Not determined |

1.2. Relevant identified uses of the substance or mixture and uses advised against

| | |
|------------------------|------------------------------------------------------------------|
| Recommended Use | Pharmaceutical product used for allergic reactions (anaphylaxis) |
|------------------------|------------------------------------------------------------------|

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
 275 North Field Drive
 Lake Forest, Illinois 60045
 1-800-879-3477

Hospira UK Limited
 Horizon
 Honey Lane
 Hurley
 Maidenhead, SL6 6RJ
 United Kingdom

1.4. Emergency telephone number

| | |
|----------------------------|-------------------------------------|
| Emergency Telephone | CHEMTREC (24 hours): 1-800-424-9300 |
| E-mail address | pfizer-MSDS@pfizer.com |

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Not classified as hazardous

2.2. Label elements

| | |
|--------------------|----------------|
| Signal word | Not Classified |
|--------------------|----------------|

| | |
|--------------------------|---------------------------------------------------------------------------------|
| Hazard statements | Not classified in accordance with international standards for workplace safety. |
|--------------------------|---------------------------------------------------------------------------------|

2.3. Other hazards

| | |
|----------------------|---------------------------------------------------------------------------------------------------------|
| Other hazards | An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8). |
|----------------------|---------------------------------------------------------------------------------------------------------|

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 2 / 12
Version 1.02

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances
Substances Not applicable

3.2 Mixtures

Hazardous

| Chemical name | Weight-% | REACH Registration Number | EC No | Classification according to Regulation (EC) No. 1272/2008 [CLP] | Specific concentration limit (SCL) | M-Factor | M-Factor (long-term) |
|----------------------------------|----------|---------------------------|-----------|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|-------------------|----------------------|
| Sodium bisulfite 7631-90-5 | <2.0 | | 231-548-0 | Acute Tox. 4 (H302) (EUH031) | Not Listed | No data available | No data available |
| SODIUM CHLORIDE 7647-14-5 | * | | 231-598-3 | No data available | Not Listed | No data available | No data available |
| Epinephrine 51-43-4 | 1.0 | | 200-098-7 | Acute Tox. 2 (H300) Acute Tox. 2 (H310) | Not Listed | No data available | No data available |
| + Hydrochloric Acid 7647-01-0 | ** | | 231-595-7 | Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas | Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1B :: C≥25% Skin Irrit. 2 :: 10%≤C<25% STOT SE 3 :: C≥10% | No data available | No data available |

NonHazardous

| Chemical name | Weight-% | REACH Registration Number | EC No | Classification according to Regulation (EC) No. 1272/2008 [CLP] | Specific concentration limit (SCL) | M-Factor | M-Factor (long-term) |
|---------------------------|----------|---------------------------|-----------|-----------------------------------------------------------------|------------------------------------|-------------------|----------------------|
| Water 7732-18-5 | * | | 231-791-2 | No data available | Not Listed | No data available | No data available |
| Sodium citrate 68-04-2 | * | | 200-675-3 | No data available | Not Listed | No data available | No data available |

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate
No information available

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 3 / 12
Version 1.02

| Chemical name | Oral LD50 | Dermal LD50 | Inhalation LC50 - 4 hour - dust/mist - mg/L | Inhalation LC50 - 4 hour - vapor - mg/L | Inhalation LC50 - 4 hour - gas - ppm |
|----------------------------------|-------------------|-------------------|---------------------------------------------|-----------------------------------------|--------------------------------------|
| Water 7732-18-5 | 89838.9 | No data available | No data available | No data available | No data available |
| Sodium bisulfite 7631-90-5 | 1310 | No data available | No data available | No data available | No data available |
| SODIUM CHLORIDE 7647-14-5 | 3000 | 10000 | No data available | No data available | No data available |
| Epinephrine 51-43-4 | No data available | 62 | No data available | No data available | No data available |
| + Hydrochloric Acid 7647-01-0 | 238 | 5010 | No data available | No data available | 563.3022 |

Additional information

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

| | |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Inhalation | Remove to fresh air. Seek immediate medical attention/advice. |
| Eye contact | Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician. |
| Skin contact | Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention. |
| Ingestion | Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. |

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO₂, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 4 / 12
Version 1.02

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium bisulfite

ACGIH TLV

5 mg/m³

Denmark

5 mg/m³

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 5 / 12
Version 1.02

| | |
|----------------------------|-------------------------------------|
| France | 5 mg/m ³ |
| Ireland | 5 mg/m ³ |
| | STEL: 15 mg/m ³ |
| Russia | MAC: 5 mg/m ³ |
| Spain | 5 mg/m ³ |
| Switzerland | 5 mg/m ³ |
| OSHA PEL | (vacated) TWA: 5 mg/m ³ |
| United Kingdom | TWA: 5 mg/m ³ |
| | STEL: 15 mg/m ³ |
| SODIUM CHLORIDE | |
| Latvia | 5 mg/m ³ |
| Russia | MAC: 5 mg/m ³ |
| + Hydrochloric Acid | |
| ACGIH OEL (Ceiling) | 2 ppm |
| ACGIH TLV | Ceiling: 2 ppm |
| Austria | 5 ppm |
| | 8 mg/m ³ |
| | STEL 10 ppm |
| | STEL 15 mg/m ³ |
| Bulgaria | STEL: 10 ppm |
| | STEL: 15.0 mg/m ³ |
| | 5 ppm |
| | 8.0 mg/m ³ |
| Czech Republic | 8 mg/m ³ |
| | Ceiling: 15 mg/m ³ |
| Denmark | Ceiling: 5 ppm |
| | Ceiling: 8 mg/m ³ |
| Estonia | 5 ppm |
| | 8 mg/m ³ |
| | STEL: 10 ppm |
| | STEL: 15 mg/m ³ |
| European Union | TWA: 5 ppm |
| | TWA: 8 mg/m ³ |
| | STEL: 10 ppm |
| | STEL: 15 mg/m ³ |
| Finland | STEL: 5 ppm |
| | STEL: 7.6 mg/m ³ |
| Germany | 2 ppm |
| | 3.0 mg/m ³ |
| | Ceiling / Peak: 4 ppm |
| | Ceiling / Peak: 6 mg/m ³ |
| Germany | 2 ppm |
| | 3 mg/m ³ |
| Hungary | 8 mg/m ³ |
| | STEL: 16 mg/m ³ |
| Ireland | 8 mg/m ³ |
| | 5 ppm |
| | STEL: 10 ppm |
| | STEL: 15 mg/m ³ |
| Italy | 5 ppm |
| | 8 mg/m ³ |
| | STEL: 10 ppm |
| | STEL: 15 mg/m ³ |
| Ceiling Limit Value | 2 ppm |
| | 3.0 mg/m ³ |
| Latvia | 5 ppm |
| | 8 mg/m ³ |
| | STEL: 10 ppm |
| | STEL: 15 mg/m ³ |
| Netherlands | 8 mg/m ³ |

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 6 / 12
Version 1.02

| | |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| Poland | STEL: 15 mg/m ³ STEL: 10 mg/m ³ 5 mg/m ³ |
| Romania | 5 ppm 8 mg/m ³ STEL: 10 ppm |
| Russia | STEL: 15 mg/m ³ MAC: 5 mg/m ³ |
| Slovakia | 5 ppm 8.0 mg/m ³ |
| Spain | 5 ppm 7.6 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³ |
| Switzerland | 2 ppm 3 mg/m ³ STEL: 4 ppm STEL: 6 mg/m ³ |
| U.S. - OSHA - Final PELs - Ceiling Limits | 5 ppm 7 mg/m ³ |
| OSHA PEL | (vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m ³ Ceiling: 5 ppm Ceiling: 7 mg/m ³ |
| United Kingdom | TWA: 1 ppm TWA: 2 mg/m ³ STEL: 5 ppm STEL: 8 mg/m ³ |

SODIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Epinephrine

Pfizer Occupational Exposure Band (OEB): OEB 4 - Skin (control exposure to the range of 1ug/m³ to <10ug/m³, provide additional precautions to protect from skin contact)

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental exposure controls

No information available.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Wear impervious protective clothing to prevent skin contact – consider use of disposable clothing where appropriate. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 7 / 12
Version 1.02

Respiratory protection Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

| | |
|-------------------|---------------------------|
| Physical state | Liquid |
| Color | Clear Colorless |
| Odor | No information available. |
| Odor threshold | No information available |
| Molecular formula | Mixture |
| Molecular weight | Mixture |

Property

Values

| | |
|--------------------------------|--------------------------|
| pH | 2.2-5.0 |
| Melting point / freezing point | No data available |
| Boiling point / boiling range | |
| Flash point | No information available |
| Evaporation rate | No data available |
| Flammability (solid, gas) | No data available |
| Flammability Limit in Air | |
| Upper flammability limit: | No data available |
| Lower flammability limit: | No data available |
| Vapor pressure | No data available |
| Vapor density | No data available |
| Relative density | ~1 |
| Water solubility | No data available |
| Solubility(ies) | Soluble Water |
| Partition coefficient | No data available |
| Autoignition temperature | No data available |
| Decomposition temperature | No data available |
| Kinematic viscosity | No data available |
| Dynamic viscosity | No data available |
| Particle characteristics | |
| Particle Size | No information available |
| Particle Size Distribution | No information available |
| Explosive properties | No information available |

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 8 / 12
Version 1.02

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Short term May be absorbed through the skin and cause systemic effects. May be absorbed through mucous membranes and cause systemic effects.

Known Clinical Effects: Adverse effects associated with therapeutic use include increased heart rate (tachycardia), palpitations, sweating, nausea, vomiting, difficulty breathing, dizziness, weakness, headache, anxiety, nervousness.

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

Epinephrine

Rat Dermal LD50 62 mg/kg

Rat Oral LD50 30 mg/kg

| Chemical name | Oral LD50 | Dermal LD50 | Inhalation LC50 |
|---------------------|-------------------------|--------------------------|-------------------------|
| Water | > 90 mL/kg (Rat) | - | - |
| Sodium bisulfite | = 1310 mg/kg (Rat) | - | - |
| SODIUM CHLORIDE | = 3 g/kg (Rat) | > 10000 mg/kg (Rabbit) | > 42 mg/L (Rat) 1 h |
| Epinephrine | | = 62 mg/kg (Rat) | - |
| + Hydrochloric Acid | 238 - 277 mg/kg (Rat) | > 5010 mg/kg (Rabbit) | = 1.68 mg/L (Rat) 1 h |

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

+ Hydrochloric Acid

Skin irritation Severe

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 9 / 12
Version 1.02

Eye irritation Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Epinephrine

Embryo / Fetal Development Rat Intravenous Dose not specified Not teratogenic
Embryo / Fetal Development Rabbit Subcutaneous 30 times human dose LOAEL Developmental toxicity
Embryo / Fetal Development Mouse Subcutaneous 7 times human dose LOAEL Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Epinephrine

Bacterial Mutagenicity (Ames) *Salmonella* Negative
Sister Chromatid Exchange Negative with activation
Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Equivocal without activation

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Micronucleus Rat Negative

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Sodium bisulfite

IARC

Group 3 (Not Classifiable)

+ Hydrochloric Acid

IARC

Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should be avoided.

12.1. Toxicity

No information available

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 10 / 12
Version 1.02

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

| Chemical name | PBT and vPvB assessment |
|---------------------|---------------------------------------------------------------|
| Sodium bisulfite | The substance is not PBT / vPvB PBT assessment does not apply |
| Sodium citrate | The substance is not PBT / vPvB PBT assessment does not apply |
| SODIUM CHLORIDE | The substance is not PBT / vPvB PBT assessment does not apply |
| + Hydrochloric Acid | The substance is not PBT / vPvB PBT assessment does not apply |

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Other Information

The US Federal EPA waste listing for epinephrine does not include epinephrine salts. Disposal should be performed in accordance with all federal, state, and local regulatory requirements.

| Chemical name | RCRA - F Series Wastes | RCRA - K Series Wastes | RCRA - P Series Wastes | RCRA - U Series Wastes |
|---------------|------------------------|------------------------|------------------------|------------------------|
| Epinephrine | - | - | Present | - |

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %

Not Listed

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
 Revision date 06-Dec-2021

Page 11 / 12
 Version 1.02

| | |
|-------------------------------------------------------------------------|--------------------------|
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | 231-791-2 |
| AICS | Present |
| Sodium bisulfite | |
| CERCLA/SARA Section 313 de minimus % | Not Listed |
| Hazardous Substances RQs | 5000 lb |
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | 231-548-0 |
| AICS | Present |
| Sodium citrate | |
| CERCLA/SARA Section 313 de minimus % | Not Listed |
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | 200-675-3 |
| AICS | Present |
| Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) | Schedule 5 |
| SODIUM CHLORIDE | |
| CERCLA/SARA Section 313 de minimus % | Not Listed |
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | 231-598-3 |
| AICS | Present |
| Epinephrine | |
| CERCLA/SARA Section 313 de minimus % | Not Listed |
| Hazardous Substances RQs | 1000 lb |
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | 200-098-7 |
| AICS | Present |
| Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) | Schedule 3 Schedule 4 |
| + Hydrochloric Acid | |
| CERCLA/SARA Section 313 de minimus % | 1.0 % |
| Hazardous Substances RQs | 5000 lb |
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | 231-595-7 |
| AICS | Present |
| Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) | Schedule 5 Schedule 6 |

| Chemical name | French RG number | Title |
|-------------------------------|------------------|-------|
| Sodium bisulfite 7631-90-5 | RG 66 | - |
| SODIUM CHLORIDE 7647-14-5 | RG 78 | - |

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

| Chemical name | Restricted substance per REACH Annex XVII | Substance subject to authorization per REACH Annex XIV |
|-----------------------|-------------------------------------------|--------------------------------------------------------|
| Epinephrine - 51-43-4 | Use restricted. See item 75. | |

SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)
Revision date 06-Dec-2021

Page 12 / 12
Version 1.02

| | | |
|---------------------------------|------------------------------|--|
| + Hydrochloric Acid - 7647-01-0 | Use restricted. See item 75. | |
|---------------------------------|------------------------------|--|

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

| Chemical name | Lower-tier requirements (tons) | Upper-tier requirements (tons) |
|---------------------------------|--------------------------------|--------------------------------|
| + Hydrochloric Acid - 7647-01-0 | 25 | 250 |

| Chemical name | Plant protection products directive (91/414/EEC) |
|-----------------------------|--------------------------------------------------|
| SODIUM CHLORIDE - 7647-14-5 | Plant protection agent |

| Chemical name | EU - Biocides |
|---------------------------------|-------------------------------------------------------------------------------------------------------|
| + Hydrochloric Acid - 7647-01-0 | Product-type 2: Disinfectants and algaecides not intended for direct application to humans or animals |

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed Acute toxicity, dermal-Cat.2; H310 - Fatal in contact with skin Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Safety data sheets for individual ingredients. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date 06-Dec-2021

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.